Nevro Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Nevro Corp. to present at Wells Fargo Healthcare Conference and Morgan Stanley Global Healthcare Conference.

REDWOOD CITY, Calif., Aug. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences:

• On September 7, 2023, Kevin Thornal, Chief Executive Officer and President, and Rod MacLeod, Chief Financial Officer will present at the Wells Fargo Healthcare Conference at 4:30 PM ET at the Encore Boston Harbor Hotel in Boston, MA.
• On September 11, 2023, Kevin Thornal, Chief Executive Officer and President, and Rod MacLeod, Chief Financial Officer will present at the Morgan Stanley 21^st Annual Global Healthcare Conference at 12:55 PM ET at the Sheraton New York Times Square Hotel in New York, NY.

A webcast of these events, as well as archived recordings, will be available in the Investors section of Nevro's website at www.nevro.com.

Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb, with and without surgery, and painful diabetic neuropathy.

Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Greg Chodaczek
347-620-7010
ir@nevro.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-participation-in-upcoming-investor-conferences-301907563.html

SOURCE Nevro Corp.